Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hector Murro"'
Autor:
Hector Murro, Miguel de Tezanos Pinto, Maria Elisa Riva, Veronica Ventriglia, Beatriz Moiraghi, Jorge Milone, Emilio Lanari, Raquel Bengió, Michele Bianchini, Eduardo Bullorsky, Irene Larripa
Publikováno v:
Leukemia & Lymphoma. 52:1720-1726
In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or los
Autor:
Virginia Lombardi, Alicia Magarinos, Carolina Pavlovsky, Isabel Giere, Francisco Lastiri, Miguel A. Pavlovsky, Pedro Negri Aranguren, Valentin Labanca, Isolda Fernandez, Santiago Pavlovsky, Beatriz Moiraghi, Lem Martinez, Rosario Uriarte, Raquel Bengió, Hector Murro, Fernanda Garcia Reinoso, Jorge Milone, Juan Jesús García
Publikováno v:
Clinical lymphoma, myelomaleukemia. 11(3)
Monitoring minimal residual disease (MRD) by real-time quantitative polymerase chain reaction (RT-PCR) in chronic myeloid leukemia (CML) patients is mandatory in the era of tyrosine kinase inhibitors. Achieving a major molecular response (MMR) at 12
Autor:
Juan Carlos Camargo García, Elena Beatriz Moiraghi, Eduardo Bullorsky, Carlos A. Doti, German Stemmelin, Hector Murro, María Gabriela Flores
Publikováno v:
Blood. 112:4267-4267
Background: Since the introduction of Imatinib (IM), the treatment of chronic myeloid leukemia (CML) experienced its most important change. As this drug became the first line for the treatment of CML, we learned that under-dosing was associated with